86200

Cyclic Citrullinated Peptide (CCP) Antibody, Quantitative

CPT 86200 represents the laboratory analysis of antibodies directed against cyclic citrullinated peptides (CCP) in a patient's serum or plasma. Citrullination is a post-translational modification of the amino acid arginine into citrulline, a process mediated by the enzyme peptidylarginine deiminase (PAD). This process occurs naturally during cell death and inflammation. In patients with a genetic predisposition (such as specific HLA-DRB1 alleles), these citrullinated proteins are perceived as 'non-self' by the immune system, triggering the production of Anti-Citrullinated Protein Antibodies (ACPAs). The 86200 test specifically uses a synthetic cyclic form of these peptides (CCP) to increase the sensitivity and specificity of the assay. Clinically, the anti-CCP test is considered one of the most specific markers for Rheumatoid Arthritis (RA), often exceeding 95% specificity, which is significantly higher than the traditional Rheumatoid Factor (RF) test. This high specificity makes it invaluable for distinguishing RA from other conditions that may cause joint pain, such as systemic lupus erythematosus (SLE), hepatitis C, or osteoarthritis. Beyond diagnosis, the anti-CCP titer has significant prognostic value. Patients who test positive for CCP antibodies tend to have a more aggressive disease course characterized by rapid radiological progression and greater joint destruction. Consequently, early detection via CPT 86200 allows rheumatologists to initiate aggressive Disease-Modifying Antirheumatic Drug (DMARD) therapy sooner, potentially preventing irreversible joint damage. The test is typically performed using enzyme-linked immunosorbent assay (ELISA) technology or automated chemiluminescent immunoassay (CLIA) platforms.

Clinical Indications

  • Suspected Rheumatoid Arthritis (RA)
  • Evaluation of early inflammatory arthritis
  • Differentiation between RA and other connective tissue diseases
  • Prognostic assessment of RA severity and potential for joint erosions
  • Evaluation of patients with undifferentiated arthritis who are seronegative for Rheumatoid Factor
  • Identification of patients at high risk for progressing from preclinical joint pain to clinical RA

Procedure Steps

  1. Verify patient identity and confirm the laboratory order for CCP antibody.
  2. Perform a standard venipuncture to collect a blood sample, typically using a serum separator tube (SST) or a plain red-top tube.
  3. Allow the blood specimen to clot at room temperature for approximately 30 minutes.
  4. Centrifuge the specimen to separate the serum from the cellular components.
  5. Aliquoted serum is transferred to a plastic transport tube if the analysis is performed at a reference lab.
  6. Prepare the laboratory assay (ELISA or CLIA) by adding patient serum to wells coated with synthetic cyclic citrullinated peptides.
  7. Incubate the sample to allow CCP antibodies, if present, to bind to the antigens.
  8. Wash the plate to remove any unbound proteins or antibodies.
  9. Add a detection conjugate (enzyme-labeled anti-human IgG) and incubate.
  10. Perform a final wash and add a substrate that produces a colorimetric or luminescent signal.
  11. Measure the signal intensity using a spectrophotometer or luminometer.
  12. Calculate the quantitative concentration of CCP antibodies based on a standard reference curve.
  13. Validate and report results in units per milliliter (U/mL).

Coding Guidelines

  • CPT 86200 should be reported once per encounter for the quantitative measurement of cyclic citrullinated peptide antibodies.
  • If the test is performed as part of a larger panel of tests, ensure that no overlapping comprehensive codes exist; however, there is currently no AMA-defined 'Arthritis Panel' that includes 86200.
  • Do not confuse 86200 with 86431 (Rheumatoid factor; quantitative), as they measure different analytes.
  • Medical necessity must be established using ICD-10-CM codes that justify inflammatory arthritis workup.
  • Check for payer-specific Local Coverage Determinations (LCDs) which may limit the frequency of testing for diagnosis versus monitoring.
  • This code is for a quantitative assay; if a qualitative screen is performed (rare), the same code is typically utilized unless otherwise specified by the payer.

Associated ICD-10 Codes